Application of Umbilical Cord Blood Stem Cells in Regenerative Medicine
Abstract
BACKGROUND: Since the first umbilical cord blood (UCB) transplant, performed 25 years ago, UCB banks have been established worldwide for the collection and cryopreservation of UCB for autologous and allogeneic transplants.
CONTENT: Much has been learned in a relatively short time on the properties of UCB hematopoietic progenitors and their clinical application. More interestingly, non-hematopoietic stem cells have been isolated from UCB. These cells can be grown and differentiated into various tissues including bone, cartilage, liver, pancreas, nerve, muscle and so on. The non-hematopoietic stem cells have an advantage over other sources of stem cells, such as embryonic stem cells or induced pluripotent stem cells, because their supply is unlimited, they can be used in autologous or allogeneic situations, they need minimal manipulation and they raise no ethical concerns. Future studies will test the potential of UCB cells for the treatment of several diseases including, among other possibilities, diabetes, arthritis, burns, neurological disorder and myocardial infarction.
SUMMARY: In addition to hematopoietic stem cells, UCB contain a large number of non-hematopoietic stem cells. In the absence of ethical concern, the unlimited supply of UCB cells explains the increasing interest of using UCB for developing regenerative medicine.
KEYWORDS: UCB, transplantation, UCB bank, HSC, MSC, CD34, CD133, VSEL
Full Text:
PDFReferences
Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi ‘s anemia by means of umbilical cord blood from an HLA-identical sibling. New Engl J Med 1989; 321: 1174-8, CrossRef.
Bone Marrow Donors Worldwide [homepage on the Internet]. Leiden, The Netherlands: Total number of cord blood units; 2015 [cited 2015 Jan 7]. Available from: https://www.bmdw.org/.
Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 2009; 44: 621-6, CrossRef.
Harris DT, Rogers I. Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther. 2007; 2: 301-9, CrossRef.
Harris DT, He X, Badowski M, Nichols JC. Regenerative medicine of the eye: A short review. In: Levicar N, Habib NA, Dimarakis I, Gordon MY, editors. Stem Cell Repair & Regeneration, Vol. 3. London: Imperial College Press; 2008. p.211-25, CrossRef.
Seaberg RM, van der Kooy D. Adult rodent neurogenic regions: The ventricular subependyma contains neural stem cells, but the dentate gyrus contains restricted progenitors. J Neurosci. 2002; 22: 1784-93, PMID.
Tropepe V, Coles BL, Chiasson BJ, Horsford DJ, Elia AJ, McInnes RR, et al. Retinal stem cells in the adult mammalian eye. Science. 2000; 287: 2032-6, CrossRef.
Seaberg RM, Smukler SR, Kieffer TJ, Enikolopov G, Asghar Z, Wheeler MB, et al. Clonal identiication of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol. 2004; 22: 1115-24, CrossRef.
Toma JG, Akhavan M, Fernandes KJ, Barnabé-Heider F, Sadikot A, Kaplan DR, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001; 3: 778-84, CrossRef.
Yoon BI, Choi YK, Kim DY. Differentiation processes of oval cells into hepatocytes: proposals based on morphological and phenotypical traits in carcinogen-treated hamster liver. Journal of Comparative Pathology 2004; 131: 1-9, CrossRef.
Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009; 147: 177-84, CrossRef.
Wagner J, Laughlin M, Petz L. Summary of the 7th Annual International Cord Blood Transplantation Symposium. Biol Blood Marrow Transplant. 2010; 16: 12-27, CrossRef.
Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002; 8: 257-60, CrossRef.
Chow R, Lin E, Tonai R, Bolanos R, Connor C, Mendoza A. Cell recovery comparison between plasma depletion/reduction- and red cell reduction-processing of umbilical cord blood. Cytotherapy. 2011; 13: 1105-19, CrossRef.
Davey S, Armitage S, Rocha V, Garnier F, Brown J, Brown CJ, et al. The London Cord Blood Bank: analysis of banking and transplantation outcome. Br J Haematol. 2004; 125: 358-65, CrossRef.
Fasouliotis SJ, Schenker JG. Human umbilical cord blood banking and transplantation: a state of the art. Eur J Obstet Gynecol Reprod Biol. 2000; 90: 13-25, CrossRef.
Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood. 2003; 101: 4233-44, CrossRef.
Kekarainen T, Mannelin S, Laine J, Jaatinen T. Optimization of immunomagnetic separation for cord blood-derived hematopoietic stem cells. BMC Cell Biol. 2006; 7: 30, PMID.
Broxmeyer HE, Gluckman E, Auerbach A, Douglas GW, Friedman H, Cooper S, et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning. 1990; 8 (Suppl 1): 76-89, CrossRef.
Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells. 2005; 23: 1105-12, CrossRef.
Basford C, Forraz N, Habibollah S, Hanger K, McGuckin C. The cord blood separation league table: A comparison of the major clinical grade harvesting techniques for cord blood stem cells. Int J Stem Cells. 2010; 3: 32-45, CrossRef.
Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, et al. Transplantation of umbilical cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005; 352: 2069-81, CrossRef.
Slatter MA, Gennery AR. Umbilical cord stem cell transplantation for primary immunodeiciencies. Expert Opin Biol Ther. 2006; 6: 555-65, CrossRef.
Harris DT. Optimizing cord blood sample cryopreservation. Cytotherapy. 2012; 14: 359-65, CrossRef.
Tedder RS, Zuckerman MA, Brink NS, Goldstone AH, Fielding A, Blair S, et al. Hepatitis B transmission from contaminated cryopreservation tank. Lancet. 1995; 346: 137-40, CrossRef.
Fountain D, Ralston M, Higins N, Gorlin JB, Uhl L, Wheeler C, et al. Liquid nitrogen freezers: A potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997; 37: 585-91, CrossRef.
Cairo MS, Wagner EL, Fraser J, Cohen G, van de Ven C, Carter SL, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) study report. Transfusion. 2005; 45: 856-66, CrossRef.
Spellman S, Hurley CK, Brady C, Phillips-Johnson L, Chow R, Laughlin M, et al. Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy. 2011; 13: 848-55, CrossRef.
Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-eficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci USA. 2003; 100: 645-50, CrossRef.
McGuckin CP, Basford C, Hanger K, Habibollah S, Forraz N. Cord blood revelations: the importance of being a irst born girl, big, on time and to a young mother! Early Hum Dev. 2007; 83: 733-41, CrossRef.
Rubinstein P, Dobrila L, Rosenield RE, Adamson JW, Migliaccio G, Migliaccio AR, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995; 92: 10119-22, CrossRef.
Vannier JP, Monconduit M, Piguet H. Comparison between 2 density gradients for separation of CFU. Biomedicine 1980; 33: 236-9, PMID.
Solves P, Mirabet V, Planelles D, Blasco I, Perales A, Carbonell-Uberos F, et al. Red blood cell depletion with a semiautomated system or hydroxyethyl starch sedimentation for routine cord blood banking: a comparative study. Transfusion. 2005; 45: 867-73, CrossRef.
Chow R, Nademanee A, Rosenthal J, Karanes C, Jaing TH, Graham ML, et al. Analysis of hematopoietic cell transplants using plasmadepleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant. 2007; 13: 1346-57, CrossRef.
Ademokun JA, Chapman C, Dunn J, Lander D, Mair K, Proctor SJ, et al. Umbilical cord blood collection and separation for haematopoietic progenitor cell banking. Bone Marrow Transplant. 1997; 19: 1023-8, CrossRef.
Lapierre V, Pellegrini N, Bardey I, Malugani C, Saas P, Garnache F, et al. Cord blood volume reduction using an automated system (Sepax) vs. a semi-automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: a comparative study. Cytotherapy. 2007; 9: 165-9, CrossRef.
Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009; 144: 468-83, CrossRef.
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in irst complete remission: system- atic review and metaanalysis of prospective clinical trials. J Am Med Assoc. 2009; 30: 2349-61, CrossRef.
Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009; 13: 6288-95, CrossRef.
Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeiciencies. Bone Marrow Transplant. 2008; 42 (Suppl 1): S49-52, CrossRef.
Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001; 344: 1815-2, CrossRef.
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placentalblood transplants from unrelated donors. N Engl J Med. 1998; 339: 1565-77, CrossRef.
Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996; 335: 157-66, CrossRef.
Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997; 337: 373-81, CrossRef.
Paulin T. Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant. 1992; 6: 48-54, PMID.
Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000; 342: 1846-54, CrossRef.
Zhang Y, Chai C, Jiang XS, Teoh SH, Leong KW. Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. Tissue Eng. 2006; 12: 2161-70, CrossRef.
Cairo MS, Wagner JE. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood. 1997; 90: 4665-78, PMID.
Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood. 2011; 117: 6083-90, CrossRef.
Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplant. 2013; 19 (Suppl 1): S74-8, CrossRef.
Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol. 2009; 147: 236-45, CrossRef.
Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009; 23: 199-204, CrossRef.
Chaurasia P, Gajzer DC, Schaniel C, D’Souza S, Hoffman R. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest. 2014; 124: 2378-95, CrossRef.
Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and beneits of double umbilical cord blood. Blood. 2010; 116: 4693-9, CrossRef.
Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010; 3: 273-83, CrossRef.
Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010; 16: 232-6, CrossRef.
Gunetti M, Ferrero I, Rustichelli D, Berger M, Gammaitoni L, Timeus F, et al. Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. Exp Hematol. 2008; 36: 235-43, CrossRef.
Ko KH, Nordon R, O’Brien TA, Symonds G, Dolnikov A. Ex vivo expansion of haematopoietic stem cells to improve engraftment in stem cell transplantation. Methods Mol Biol. 2011; 761: 249-60, CrossRef.
Madlambayan GJ, Rogers I, Purpura KA, Ito C, Yu M, Kirouac D, et al. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess. Biol Blood Marrow Transplant. 2006; 12: 1020-30, CrossRef.
Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 37: 359-66, CrossRef.
Pasino M, Lanza T, Marotta F, Scarso L, De Biasio P, Amato S, et al. Flow cytometric and functional characterization of AC133+ cells from human umbilical cord blood. Br J Haematol. 2000; 108: 793-800, CrossRef.
Forraz N, Pettengell R, Deglesne PA, McGuckin CP. AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis. Br J Haematol. 2002; 119: 516-24, CrossRef.
Pelagiadis I, Relakis K, Kalmanti L, Dimitriou H. CD133 immunomagnetic separation: effectiveness of the method for CD133(+) isolation from umbilical cord blood. Cytotherapy. 2012; 14: 701-6, CrossRef.
Meregalli M, Farini A, Belicchi M,TorrenteY. CD133(+) cells isolated from various sources and their role in future clinical perspectives. Expert Opin Biol Ther. 2010; 10: 1521-8, CrossRef.
Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M. Isolation and characterization of human CD34(–) Lin(–) and CD34(+) Lin(–) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood. 2000; 95: 2813-20, PMID.
U.S. Food and Drug Administration [homepage on the internet]. Silverspring: CFR - Code of Federal Regulations Title 21; 2014 [updated 2015 Jan 8; cited 2015 Jan 9]. Available from: http://www.accessdata.fda.gov/.
Blake JM, Nicoud IB, Weber D, Voorhies H, Guthrie KA, Heimfeld S, et al. Improved immunomagnetic enrichment of CD34(+) cells from umbilical cord blood using the CliniMACS cell separation system. Cytotherapy. 2012; 14: 818-22, CrossRef.
Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care. 2011; 34: 2567-9, CrossRef.
Morishita T, Uzui H, Nakano A, Mitsuke Y, Geshi T, Ueda T, et al. Number of endothelial progenitor cells in peripheral artery disease as a marker of severity and association with pentraxin-3, malondialdehyde-modiied low-density lipoprotein and membrane type-1 matrix metalloproteinase. J Atheroscler Thromb. 2012; 19: 149-58, CrossRef.
Perotti C, Arici V, Cervio M, Del Fante C, Calliada F, Gnecchi M, et al. Allogeneic lethally irradiated cord blood mononuclear cells in no-option critical limb ischemia: a "box of rain". Stem Cells Dev. 2013; 22: 2806-12, CrossRef.
Jurga M, Forraz N, Basford C, Atzeni G, Trevelyan AJ, Habibollah S, et al. Neurogenic properties and a clinical relevance of multipotent stem cells derived from cord blood samples stored in the biobanks. Stem Cells Dev. 2012; 21: 923-36, CrossRef.
Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? Lancet. 2005; 365: 891-900, CrossRef.
Vannucci RC, Connor JR, Mauger DT, Palmer C, Smith MB, Towighi J, et al. Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res. 1999; 55: 158-63, CrossRef.
Pimentel-Coelho PM, Magalhaes ES, Lopes LM, deAzevedo LC, Santiago MF, Mendez-Otero R. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: Functional outcome related to neuroprotection in the striatum. Stem Cell Dev. 2010; 19: 351-6, CrossRef.
Vendrame M, Cassady J, Newcomb J, Butler T, Pennypacker KR, Zigova T, et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke. 2004; 35: 2390-5, CrossRef.
Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, et al. Intravenous administration of human umbilical cord blood reduces behavioral deicits after stroke in rats. Stroke. 2001; 32: 2682-8, CrossRef.
Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006; 59: 244-9, CrossRef.
Dalous J, Pansiot J, Pham H, Chatel P, Nadaraja C, D’Agostino ID. Use of human umbilical cord blood mononuclear cells to prevent perinatal brain injury: A preclinical study. Stem Cells Dev. 2013; 22: 169-79, CrossRef.
Sobani ZA, Quadri SA, Enam SA. Stem cells for spinal cord regeneration: current status. Surg Neurol Int. 2010; 1: 93, CrossRef.
Garbossa D, Boido M, Fontanella M, Fronda C, Ducati A, Vercelli A. Recent therapeutic strategies for spinal cord injury treatment: possible role of stem cells. Neurosurg Rev. 2012; 35: 293-311, CrossRef.
Gurudutta GU, Satija NK, Singh VK, Verma YK, Gupta P, Tripathi RP. Stem cell therapy: A novel & futuristic treatment modality for disaster injuries. Indian J Med Res. 2012; 135: 15-25, CrossRef.
Ruff CA, Wilcox JT, Fehlings MG. Cell-based transplantation strategies to promote plasticity following spinal cord injury. Exp Neurol. 2012; 235: 78-90, CrossRef.
Sandner B, Prang P, Rivera FJ, Aigner L, Blesch A, Weidner N. Neural stem cells for spinal cord repair. Cell Tissue Res. 2012; 349: 349-62, CrossRef.
Ning G, Tang L, Wu Q, Li Y, Li Y, Zhang C, et al. Human umbilical cord blood stem cells for spinal cord injury: early transplantation results in better local angiogenesis. Regen Med. 2013; 8: 271-81, CrossRef.
Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010, NLMID.
Azouvi P, Vallat-Azouvi C, Belmont A. Cognitive deicits after traumatic coma. Prog Brain Res. 2009; 177: 89-110, CrossRef.
Wong D, Dahm J, Ponsford J. Factor structure of the depression anxiety stress scales in individuals with traumatic brain injury. Brain Inj. 2013; 27: 1377-82, CrossRef.
Kaneko Y, Tajiri N, Yu S, Hayashi T, Stahl CE, Bae E, et al. Nestin overexpression precedes caspase-3 upregulation in rats exposed to controlled cortical impact traumatic brain injury. Cell Med. 2012; 4: 55-63, CrossRef.
Sanberg PR, Eve DJ, Metcalf Borlongan CV. Advantages and challenges of alternative sources of adult-derived stem cells for brain repair in stroke. Prog. Brain Res. 2012; 201: 99-117, CrossRef.
Ilic D, Miere C, Lazic E. Umbilical cord blood cells: clinical trials in non-hematological disorders. Br Med Bull. 2012; 102: 43-57, CrossRef.
de la pena I, Sanberg PR, Acosta S, Lin SZ, Borlongan CV. Umbilical cord blood cell and granulocyte-colony stimulating factor: combination therapy for traumatic brain injury. Regen Med. 2014; 9: 409-12, CrossRef.
Garbuzova-Davis S, Sanberg CD, Kuzmin-Nichols N, Willing AE, Gemma C, Bickford PC, et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS ONE. 2008; 3: e2494, CrossRef.
Kurtzberg J, Kosaras B, Stephens C, Snyder EY. Umbilical cordblood cells engraft and differentiate into neural tissue after human transplantation. Biol Blood Marrow Transplant. 2003; 9: 128, CrossRef.
Goldman SA, Schanz S, Windrem MS. Stem cell-based strategies for treating pediatric disorders of myelin. Hum Mol Genet. 2008; 17: R76-83, CrossRef.
Tracy ET, Zhang CY, Gentry T, Shoulars KV, Kurtzberg J. Isolation and expansion of oligodendrocyte progenitor cells from cryopreserved human umbilical cord blood. Cytotherapy 2011; 13: 722-9, CrossRef.
Liu R, Zhang Z, Lu Z, Borlongan C, Pan J, Chen J, et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinlammation and remyelination. Stem Cells Dev. 2013; 22: 1053-62, CrossRef.
Steenblock D, Payne AG. Umbilical cord stem cell therapy: The gift of healing from healthy newborns. [n.p]: Basic Health Publication; 2006.
DOI: https://doi.org/10.18585/inabj.v6i3.25
Copyright (c) 2014 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
